Protective immunity against disparate tumors is mediated by a nonpolymorphic MHC class I molecule

Journal of Immunology

Volumn 174, Issue 9, 2005, Pages 5367-5374

  Chiang, Eugene Y ^a   Stroynowski, Iwona ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN; PROTEIN Q9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL MEMORY; LEWIS CARCINOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; TUMOR IMMUNITY;

EID: 17844388378     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.9.5367     Document Type: Article

References (39)

1. Chang, C.-C., M. Campoli, and S. Ferrone. 2003. HLA class I defects in malignant lesions: what have we learned? Keio J. Med. 52:220.
2. Srivastava, P. K. 2000. Immunotherapy of cancer: lessons from mice. Nat. Immunol. 1:363.
3. Renkvist, N., C. Castelli, P. F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:3.
4. Weber, J. 2002. Peptide vaccines for cancer. Cancer Invest. 20:208.
5. Singh-Jasuja, H., N. P. N. Emmerich, and H.-G. Rammensee. 2004. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53:187.
6. van der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51.
7. Kirkin, A. F., K. N. Dzhandzhugazyan, and J. Zeuthen. 2002. Cancer/testis antigens: structural and immunobiological properties. Cancer Invest. 20:222.
8. + T cells. J. Immunol. 163:6330.
9. He, X., P. Tabaczewski, J. Ho, I. Stroynowski, and K. C. Garcia. 2001. Promiscuous antigen presentation by the non-classical MHC class Ib Qa-2 is enabled by a shallow, hydrophobic groove and self-stabilized conformation. Structure 9:1213.
10. Joyce, S., P. Tabaczewski, R. H. Angelettid, S. G. Nathenson, and I. Stroynowski. 1994. A nonpolymorphic major histocompatibility complex class Ib molecule binds a large array of diverse self-peptides. J. Exp. Med. 179:579.
11. Tabaczewski, P., and I. Stroynowski. 1994. Expression of secreted and glycosylphosphatidylinositol-bound Qa-2 molecules is dependent on functional TAP-2 peptide transporter. J. Immunol. 152:5268.
12. Tabaczewski, P., E. Chiang, M. Henson, and I. Stroynowski. 1997. Alternative peptide binding motifs of Qa-2 class Ib molecules define rules for binding of self and nonself peptides. J. Immunol. 159:2771.
13. Ungchusri, T., E. Y. Chiang, G. Brown, M. Chen, P. Tabaczewski, L. Timares, and I. Stroynowski. 2001. Widespread expression of the nonclassical class I Qa-2 antigens in hemopoietic and nonhemopoietic cells. Immunogenetics 53:455.
14. Chiang, E. Y., M. Henson, and I. Stroynowski. 2003. Correction of defects responsible for impaired Qa-2 class Ib MHC expression on melanoma cells protects mice from tumor growth. J. Immunol. 170:4515.
15. Chiang, E. Y., and I. Stroynowski. 2004. A nonclassical MHC class 1 molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor. J. Immunol. 173:4394.
16. Chiang, E. Y., M. Henson, and I. Stroynowski. 2002. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis. J. Immunol. 168:2200.
17. Ljunggren, H.-G., and K. Karre. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants: analysis of the mechanism. J. Exp. Med. 162:1745.
18. Eisenbach, L., S. Segal, and M. Feldman. 1983. MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int. J. Cancer 32:113.
19. Darlington, G. J., H. P. Bernhard, R. A. Miller, and F. H. Ruddle. 1980. Expression of liver phenotypes in cultured mouse hepatoma cells. J. Natl. Cancer Inst. 64:809.
20. Sviderskaya, E. V., W. F. Wakeling, and D. C. Bennett. 1995. A clone, immortal line of murine melanoblasts inducible to differentiate to melanocytes. Development 121:1547.
21. Hasenkrug, K. J., J. M. Cory, and J. H. Stimpfling. 1987. Monoclonal antibodies defining mouse tissue antigens encoded by the H-2 region. Immunogenetics 25:136.
22. Jones, B., and C. A. Janeway. 1981. Cooperative interaction of B lymphocytes with antigen-specific helper T lymphocytes is MHC restricted. Nature 292:547.
23. b haplotype reveal genetic control of isotype expression. J. Immunol. 126:317.
24. Eisenbach, L., N. Hollander, L. Greenfeld, H. Yakor, S. Segal, and M. Feldman. 1984. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int. J. Cancer 34:567.
25. b antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma. J. Immunol. 141:4403.
26. Engelhard, V. H., T. N. I. Bullock, T. A. Colella, S. L. Sheasley, and D. W. Mullins. 2002. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188:136.
27. + T cells. J. Exp. Med. 198:569.
28. van Elsas, A., R. P. M. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J.-P. Medema, W. W. Overwijk, N. P. R. Restifo C. J. M. Melief, R. Offringa, and J. P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:481.
29. Mandelboim, O., G. Berke, M. Fridkin, M. Feldman, M. Elsenstein, and L. Eisenbach. 1994. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67.
30. Mandelboim, O., E. Bar-Haim, E. Vadai, M. Fridkin, and L. Eisenbach. 1997. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas. J. Immunol. 159:6030.
31. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
32. De Backer, O., K. C. Arden, M. Borciti, V. Vantomme, C. De Smet, S. Czekay, C. S. Viars, E. De Plaen, F. Brasseur, P. Chomez, et al. 1999. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 59:3157.
33. Jager, E., M. Ringhoffer, M. Altmannsberger, M. Arand, I. Karbach, D. Jager, F. Oesch, and A. Knuth. 1997. Immunoselection in vivo: independent loss of anoma. Int. J. Cancer 71:142.
34. Parham, P. 1999. Virtual reality in the MHC. Immunol. Rev. 167:5.
35. Amadou, C., A. Kumanovics, E. P. Jones, D. Lambrecht-Washington, M. Yoshino, and K. Fisher Lindahl. 1999. The mouse major histocompatibility complex: some assembly required. Immunol. Rev. 167:211.
36. Schreuder, G. M. T., C. K. Hurley, S. G. E. Marsh, M. Lau, M. Maiers. C. Killman, and H. J. Noreen. 2001. The HLA dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/5/6 and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Eur. J. Immunogenetics 28:565.
37. Sidney, I., S. Southwood, D. L. Mann, M. A. Fernandez-Vina, M. J. Newman, and A. Sette. 2001. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum. Immunol. 62:1200.
38. Lund, O., M. Nielson, C. Kesmir, A. G. Petersen, C. Lundegaard, P. Worning, C. Sylvester-Hvid, K. Umberth, G. Roder, S. Justesen, et al. 2004. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55:797.
39. Breckpot, K., C. Heirman, C. De Greef, P. van der Bruegen, and K. Thielemans. 2004. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol. 172:2232.